

Special Issue

Precision Medicine, It Is Time to Tailor and Drive the Treatment in Rheumatic Diseases

Message from the Guest Editors

The term “precision medicine” has become increasingly popular by proposing a medical model which allows to choose a personalized treatment, tailoring therapeutic strategies to the individual characteristics of each patient. In fact, precision medicine has been defined as a new approach for disease treatment and prevention that considers individual variability in genes, lifestyle and environmental exposure. In rheumatic diseases, often characterized by wide phenotypic heterogeneity, precision medicine is still an emerging area. Recently, significant efforts have been made to better understand the pathogenetic mechanisms in several rheumatic diseases. The combination of clinical, laboratoristic, instrumental features and molecular and genetic pathways should allow to identify patients with similar disease courses and treatment responses. Therefore, through knowledge of these features, a precision medicine approach may guide the choice of treatment and the timing of its administration in order to maximize drug efficacy, determining the optimal treatment regimen for each patient. Dr. Silvia Bellando-Randone

Guest Editors

Dr. Silvia Bellando Randone
Dr. Gemma Lepri
Dr. Edda Russo

Deadline for manuscript submissions

closed (15 June 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/99558

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).